Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

NCT03660761 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Efficacy and Safety

Interventions

DRUG: apatinib
DRUG: temodar

Sponsor

Rongjie Tao